SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
